Overview

Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors

Status:
RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
A Study of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) Therapy for Patients With Advanced Solid Tumors
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Anhui Provincial Hospital
Collaborator:
Leman Biotech Co., Ltd.